Company / Capital Expenditures
BioLife Solutions, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$9.5M
FY2025
5-year range
$3.2M / $10.4M
FY2021-FY2025
Trend
+193.7%
vs FY2024
Sector context
#108 of 145
Health Care
What the data says
At $9M, BioLife Solutions, Inc.'s capital expenditures ranks #108 of 145 in the Health Care sector. Capital Expenditures returned to growth in FY2025 after 2 years of decline, reaching $9M.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of +37.0%.
Improved from $6M to $9M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -3.0%
- 5-Year CAGR
- +37.0%
- 10-Year CAGR
- -
Sector benchmark
#108 of 145 in Health CareTop 74% of 145This company $9.5M Sector average $268.6M
▼
-96.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +37.0%, indicating consistent growth.
- In FY2025, capital expenditures increased 193.7% year-over-year.
- Ranks #108 out of 145 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 4.67 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.5M | +193.7% |
| FY2024 | $3.2M | -49.4% |
| FY2023 | $6.4M | -38.6% |
| FY2022 | $10.4M | +23.9% |
| FY2021 | $8.4M | +327.6% |
| FY2020 | $2.0M | +190.5% |
| FY2019 | $675.0K | +1546.3% |
| FY2018 | $41.0K | -71.5% |
| FY2017 | $144.0K | +0.3% |
| FY2016 | $143.5K | +7.1% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026